

# Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/GA7426668966EN.html>

Date: February 2023

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: GA7426668966EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the "CAR-T Therapy in Haematological Malignancy Industry Forecast" looks at past sales and reviews total world CAR-T Therapy in Haematological Malignancy sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy in Haematological Malignancy sales for 2023 through 2029. With CAR-T Therapy in Haematological Malignancy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world CAR-T Therapy in Haematological Malignancy industry.

This Insight Report provides a comprehensive analysis of the global CAR-T Therapy in Haematological Malignancy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR-T Therapy in Haematological Malignancy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global CAR-T Therapy in Haematological Malignancy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy in Haematological Malignancy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-

## T Therapy in Haematological Malignancy.

The global CAR-T Therapy in Haematological Malignancy market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key CAR-T Therapy in Haematological Malignancy players cover Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy in Haematological Malignancy market by product type, application, key players and key regions and countries.

### Market Segmentation:

#### Segmentation by type

Allogeneic

Autologous

#### Segmentation by application

Hospitals

Cancer Research Centers

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Celgene (Juno Therapeutics)

Novartis

Gilead (Kite Pharma)

Pfizer

CARsgen Therapeutics

Autolus Therapeutics

Aurora BioPharma

Sorrento Therapeutics

Mustang Bio

Bluebird Bio

Collectis

Allogene Therapeutics

Celyad

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2018-2029
  - 2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 CAR-T Therapy in Haematological Malignancy Segment by Type
  - 2.2.1 Allogeneic
  - 2.2.2 Autologous
- 2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type
  - 2.3.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029)
  - 2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
- 2.4 CAR-T Therapy in Haematological Malignancy Segment by Application
  - 2.4.1 Hospitals
  - 2.4.2 Cancer Research Centers
  - 2.4.3 Others
- 2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application
  - 2.5.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029)
  - 2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

### 3 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SIZE BY PLAYER

### 3.1 CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players

3.1.1 Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023)

3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2023)

### 3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

### 3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

### 3.4 New Products and Potential Entrants

### 3.5 Mergers & Acquisitions, Expansion

## 4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY BY REGIONS

4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions (2018-2023)

4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)

4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)

4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)

4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)

## 5 AMERICAS

5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)

5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)

5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023)

6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)

6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## **7 EUROPE**

7.1 Europe CAR-T Therapy in Haematological Malignancy by Country (2018-2023)

7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)

7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Region (2018-2023)

8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)

8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 GLOBAL CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET FORECAST**

10.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)

10.1.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)

10.1.2 Americas CAR-T Therapy in Haematological Malignancy Forecast

10.1.3 APAC CAR-T Therapy in Haematological Malignancy Forecast

10.1.4 Europe CAR-T Therapy in Haematological Malignancy Forecast

10.1.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast

10.2 Americas CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)

10.2.1 United States CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.2 Canada CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.3 Mexico CAR-T Therapy in Haematological Malignancy Market Forecast

10.2.4 Brazil CAR-T Therapy in Haematological Malignancy Market Forecast

10.3 APAC CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)

10.3.1 China CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.2 Japan CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.3 Korea CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.5 India CAR-T Therapy in Haematological Malignancy Market Forecast

10.3.6 Australia CAR-T Therapy in Haematological Malignancy Market Forecast

10.4 Europe CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)

10.4.1 Germany CAR-T Therapy in Haematological Malignancy Market Forecast

10.4.2 France CAR-T Therapy in Haematological Malignancy Market Forecast

- 10.4.3 UK CAR-T Therapy in Haematological Malignancy Market Forecast
- 10.4.4 Italy CAR-T Therapy in Haematological Malignancy Market Forecast
- 10.4.5 Russia CAR-T Therapy in Haematological Malignancy Market Forecast
- 10.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)
  - 10.5.1 Egypt CAR-T Therapy in Haematological Malignancy Market Forecast
  - 10.5.2 South Africa CAR-T Therapy in Haematological Malignancy Market Forecast
  - 10.5.3 Israel CAR-T Therapy in Haematological Malignancy Market Forecast
  - 10.5.4 Turkey CAR-T Therapy in Haematological Malignancy Market Forecast
  - 10.5.5 GCC Countries CAR-T Therapy in Haematological Malignancy Market Forecast
- 10.6 Global CAR-T Therapy in Haematological Malignancy Forecast by Type (2024-2029)
- 10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Application (2024-2029)

## **11 KEY PLAYERS ANALYSIS**

- 11.1 Celgene (Juno Therapeutics)
  - 11.1.1 Celgene (Juno Therapeutics) Company Information
  - 11.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.1.4 Celgene (Juno Therapeutics) Main Business Overview
  - 11.1.5 Celgene (Juno Therapeutics) Latest Developments
- 11.2 Novartis
  - 11.2.1 Novartis Company Information
  - 11.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.2.4 Novartis Main Business Overview
  - 11.2.5 Novartis Latest Developments
- 11.3 Gilead (Kite Pharma)
  - 11.3.1 Gilead (Kite Pharma) Company Information
  - 11.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.3.4 Gilead (Kite Pharma) Main Business Overview

- 11.3.5 Gilead (Kite Pharma) Latest Developments
- 11.4 Pfizer
  - 11.4.1 Pfizer Company Information
  - 11.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.4.4 Pfizer Main Business Overview
  - 11.4.5 Pfizer Latest Developments
- 11.5 CARsgen Therapeutics
  - 11.5.1 CARsgen Therapeutics Company Information
  - 11.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.5.4 CARsgen Therapeutics Main Business Overview
  - 11.5.5 CARsgen Therapeutics Latest Developments
- 11.6 Autolus Therapeutics
  - 11.6.1 Autolus Therapeutics Company Information
  - 11.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.6.4 Autolus Therapeutics Main Business Overview
  - 11.6.5 Autolus Therapeutics Latest Developments
- 11.7 Aurora BioPharma
  - 11.7.1 Aurora BioPharma Company Information
  - 11.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.7.4 Aurora BioPharma Main Business Overview
  - 11.7.5 Aurora BioPharma Latest Developments
- 11.8 Sorrento Therapeutics
  - 11.8.1 Sorrento Therapeutics Company Information
  - 11.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
  - 11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
  - 11.8.4 Sorrento Therapeutics Main Business Overview

#### 11.8.5 Sorrento Therapeutics Latest Developments

#### 11.9 Mustang Bio

##### 11.9.1 Mustang Bio Company Information

##### 11.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered

##### 11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)

##### 11.9.4 Mustang Bio Main Business Overview

##### 11.9.5 Mustang Bio Latest Developments

#### 11.10 Bluebird Bio

##### 11.10.1 Bluebird Bio Company Information

##### 11.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered

##### 11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)

##### 11.10.4 Bluebird Bio Main Business Overview

##### 11.10.5 Bluebird Bio Latest Developments

#### 11.11 Collectis

##### 11.11.1 Collectis Company Information

##### 11.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Offered

##### 11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)

##### 11.11.4 Collectis Main Business Overview

##### 11.11.5 Collectis Latest Developments

#### 11.12 Allogene Therapeutics

##### 11.12.1 Allogene Therapeutics Company Information

##### 11.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

##### 11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)

##### 11.12.4 Allogene Therapeutics Main Business Overview

##### 11.12.5 Allogene Therapeutics Latest Developments

#### 11.13 Celyad

##### 11.13.1 Celyad Company Information

##### 11.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Offered

##### 11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)

##### 11.13.4 Celyad Main Business Overview

##### 11.13.5 Celyad Latest Developments

## 12 RESEARCH FINDINGS AND CONCLUSION

## List Of Tables

### LIST OF TABLES

Table 1. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Allogeneic

Table 3. Major Players of Autologous

Table 4. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Table 7. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Table 10. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player (2018-2023)

Table 12. CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

Table 13. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)

Table 18. Global CAR-T Therapy in Haematological Malignancy Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by

Country (2018-2023) & (\$ Millions)

Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)

Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Table 24. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)

Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Table 30. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)

Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of CAR-T Therapy in Haematological Malignancy

Table 45. Key Market Challenges & Risks of CAR-T Therapy in Haematological Malignancy

Table 46. Key Industry Trends of CAR-T Therapy in Haematological Malignancy

Table 47. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. Celgene (Juno Therapeutics) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 52. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered

Table 53. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. Celgene (Juno Therapeutics) Main Business

Table 55. Celgene (Juno Therapeutics) Latest Developments

Table 56. Novartis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 57. Novartis CAR-T Therapy in Haematological Malignancy Product Offered

Table 58. Novartis Main Business

Table 59. Novartis CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Novartis Latest Developments

Table 61. Gilead (Kite Pharma) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 62. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product

Offered

Table 63. Gilead (Kite Pharma) Main Business

Table 64. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 65. Gilead (Kite Pharma) Latest Developments

Table 66. Pfizer Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 67. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered

Table 68. Pfizer Main Business

Table 69. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. Pfizer Latest Developments

Table 71. CARsgen Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 72. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 73. CARsgen Therapeutics Main Business

Table 74. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. CARsgen Therapeutics Latest Developments

Table 76. Autolus Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 77. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 78. Autolus Therapeutics Main Business

Table 79. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. Autolus Therapeutics Latest Developments

Table 81. Aurora BioPharma Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 82. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered

Table 83. Aurora BioPharma Main Business

Table 84. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. Aurora BioPharma Latest Developments

Table 86. Sorrento Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product

Offered

Table 88. Sorrento Therapeutics Main Business

Table 89. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Sorrento Therapeutics Latest Developments

Table 91. Mustang Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 92. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 93. Mustang Bio Main Business

Table 94. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. Mustang Bio Latest Developments

Table 96. Bluebird Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 97. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 98. Bluebird Bio Main Business

Table 99. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. Bluebird Bio Latest Developments

Table 101. Collectis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 102. Collectis CAR-T Therapy in Haematological Malignancy Product Offered

Table 103. Collectis CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 104. Collectis Main Business

Table 105. Collectis Latest Developments

Table 106. Allogene Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 107. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 108. Allogene Therapeutics Main Business

Table 109. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 110. Allogene Therapeutics Latest Developments

Table 111. Celyad Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors

Table 112. Celyad CAR-T Therapy in Haematological Malignancy Product Offered

Table 113. Celyad Main Business

Table 114. Celyad CAR-T Therapy in Haematological Malignancy Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

Table 115. Celyad Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. CAR-T Therapy in Haematological Malignancy Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2022)

Figure 8. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022

Figure 10. CAR-T Therapy in Haematological Malignancy in Hospitals

Figure 11. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2018-2023) & (\$ Millions)

Figure 12. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers

Figure 13. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2018-2023) & (\$ Millions)

Figure 14. CAR-T Therapy in Haematological Malignancy in Others

Figure 15. Global CAR-T Therapy in Haematological Malignancy Market: Others (2018-2023) & (\$ Millions)

Figure 16. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022

Figure 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player in 2022

Figure 18. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)

Figure 19. Americas CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 (\$ Millions)

Figure 20. APAC CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 (\$ Millions)

Figure 21. Europe CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 (\$ Millions)

Figure 23. Americas CAR-T Therapy in Haematological Malignancy Value Market Share by Country in 2022

Figure 24. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region in 2022

Figure 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022

Figure 30. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022

Figure 31. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country in 2022

Figure 38. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Figure 39. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Figure 40. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France CAR-T Therapy in Haematological Malignancy Market Size Growth

2018-2023 (\$ Millions)

Figure 42. UK CAR-T Therapy in Haematological Malignancy Market Size Growth

2018-2023 (\$ Millions)

Figure 43. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth

2018-2023 (\$ Millions)

Figure 44. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth

2018-2023 (\$ Millions)

Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)

Figure 48. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 54. APAC CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 55. Europe CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 57. United States CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 58. Canada CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 61. China CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 62. Japan CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 63. Korea CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 65. India CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 66. Australia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 67. Germany CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 68. France CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 69. UK CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 70. Italy CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 71. Russia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 72. Spain CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 75. Israel CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 (\$ Millions)

Figure 78. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2024-2029)

## I would like to order

Product name: Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/GA7426668966EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA7426668966EN.html>